{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:04:16Z","timestamp":1790661856301,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Conseil R\u00e9gional de Basse Normandie"},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French Foundation Plan Alzheimer"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejmech.2016.05.048","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T22:31:18Z","timestamp":1464215478000},"page":"283-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-5007","authenticated-orcid":false,"given":"Samir","family":"Yahiaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Hamidouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Ballandonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Sopkova","family":"de Oliveira Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Freret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boulouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.05.048_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrn2977","article-title":"The role of G protein-coupled receptors in the pathology of Alzheimer\u2019s disease","volume":"12","author":"Thathiah","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fnagi.2013.00096","article-title":"Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"5","author":"Giannoni","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2014.05.013","article-title":"SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl\/6 mice","volume":"85","author":"Lo","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2016.05.048_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbr.2007.10.008","article-title":"Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl\/6j mice","volume":"187","author":"Cachard-Chastel","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2016.05.048_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.brainres.2006.08.108","article-title":"Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia","volume":"1121","author":"Micale","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2016.05.048_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00210-003-0743-2","article-title":"BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse","volume":"367","author":"Lelong","year":"2003","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.05.048_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-011-2627-3","article-title":"5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice","volume":"222","author":"Da Silva Costa-Aze","year":"2012","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.ejmech.2016.05.048_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbr.2011.03.046","article-title":"Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice","volume":"222","author":"Da Silva Costa-Aze","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2016.05.048_bib9","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1021\/jm1007825","article-title":"5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists","volume":"53","author":"Liu","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbr.2015.07.020","article-title":"Chronic activation of 5-HT4 receptors or blockade of 5-HT6 receptors improve memory performances","volume":"293","author":"Quiedeville","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2016.05.048_bib11","doi-asserted-by":"crossref","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","article-title":"Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer\u2019s disease treatment","volume":"111","author":"Lecoutey","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib12","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel Multi-Target Directed Ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer\u2019s disease: the design of donecopride","volume":"58","author":"Rochais","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acschemneuro.5b00135","article-title":"Serotonin: a new hope in Alzheimer\u2019s disease ?","volume":"15","author":"Claeysen","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib14","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.3390\/ijms12085011","article-title":"Investigation of the structure requirement for 5-HT6 binding affinity of arylsulfonyl derivatives: a computational study","volume":"12","author":"Hao","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bmc.2010.10.033","article-title":"Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists","volume":"19","author":"Liu","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bmcl.2010.11.001","article-title":"Indole-3-piperazinyl derivatives: novel chemical class of 5-HT6 receptor antagonists","volume":"21","author":"Nirogi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.05.048_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-384976-2.00001-0","article-title":"5-HT6 medicinal chemistry","volume":"94","author":"Liu","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ejmech.2016.05.048_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2174\/1568026615666150427110420","article-title":"Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance","volume":"15","author":"Bali","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/ci0101354","article-title":"Molecular design based on 3D-pharmacophore. Application to 5-HT4 receptor","volume":"42","author":"Bureau","year":"2002","journal-title":"J.\u00a0Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.ejmech.2016.05.048_bib20","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1021\/jm200466r","article-title":"N\u2032-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features","volume":"54","author":"van Loevezijn","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.05.048_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acs.jmedchem.5b01153","article-title":"Further advances in optimizing (2-phenylcyclopropyl)methylamines as novel serotonin 2C agonists: effects on hyperlocomotion, prepulse inhibition, and cognition models","volume":"59","author":"Cheng","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ejmech.2014.12.021","article-title":"Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1\/MT2) and serotonin 5-HT2C receptor subtypes (II)","volume":"90","author":"Ettaoussi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.05.048_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A\u00a0short history of SHELX","volume":"A64","author":"Sheldrick","year":"2008","journal-title":"Acta Cryst."},{"key":"10.1016\/j.ejmech.2016.05.048_bib25","series-title":"SHELXL2014","author":"Sheldrick","year":"2014"},{"key":"10.1016\/j.ejmech.2016.05.048_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1476-5381.1993.tb13617.x","article-title":"Development of a radioligand binding assay for 5HT4 receptors in guinea pig and rat brain","volume":"109","author":"Grossman","year":"1993","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416304469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416304469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T05:35:58Z","timestamp":1556343358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416304469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":26,"alternative-id":["S0223523416304469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.048","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}